LP-935509

LP-935509 is an orally active, potent, selective, ATP-competitive and brain-penetrant inhibitor of adaptor protein-2 associated kinase 1 (AAK1) with an IC50 of 3.3 nM and a Ki of 0.9 nM, respectively. LP-935509 is also a potent inhibitor of BIKE (IC50=14 nM) and a modest inhibitor of GAK (IC50=320 nM) . LP-935509 shows antinociceptive activity. LP-935509 can be used for neuropathic pain and SARS-CoV-2 research[1].

Product Specifications

CAS Number

[1454555-29-3]

Product Name Alternative

6-Hydroxybentazone

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

AAK1; Cyclin G-associated Kinase (GAK) ; SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Infection; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/lp-935509.html

Purity

99.74

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(N1CCN(C2=NC3=C(C4=CC=CN=C4OC)C=NN3C=C2)CC1)OC(C)C

Molecular Formula

C20H24N6O3

Molecular Weight

396.44

Precautions

H315, H319, H335

References & Citations

[1]Kostich W, et al. Inhibition of AAK1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain. J Pharmacol Exp Ther. 2016 Sep;358 (3) :371-86.|[2]Mushtaq, et al. Role Of Endocytic Machinery Regulators in EGFR Traffic and Viral Entry (2021) . Theses & Dissertations. 532.